文献速递妇科

宫颈癌前瞻性影像与新辅助治疗(PRICE)研究:超声预测局部晚期宫颈癌患者放化疗联合根治性手术后部分缓解的作用

PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-01-01

研究前瞻性纳入2010年10月至2014年6月单中心108例局部晚期宫颈癌(LACC)患者中的88例,分析经阴道超声及三维能量多普勒、造影参数在治疗前及新辅助治疗2周后预测病理部分缓解的价值。结果显示两组参数存在差异,但治疗前与治疗2周后各参数的截断值敏感性与特异性均不可接受。

要点

  • 新辅助治疗2周后,部分缓解组肿瘤体积显著大于完全缓解组(P=0.019)。
  • 治疗前及治疗2周后,部分缓解组血管化指数(VI)均显著低于完全缓解组(P=0.037与P=0.024)。
  • 治疗前及治疗2周后超声参数截断值的敏感性与特异性均不可接受,不足以预测病理部分缓解。

核心结论

  • LACC患者完全缓解与部分缓解之间,治疗前及新辅助治疗2周后的超声及造影参数存在差异,但治疗前与治疗2周后超声参数的截断值敏感性与特异性均不可接受,无法预测新辅助治疗的病理部分缓解。

研究设计与样本

  • 前瞻性单中心研究,2010年10月至2014年6月筛查108例组织学证实的LACC(IB2-IVA期)女性,最终纳入88例分析。
  • 于治疗前(基线)及治疗2周后获取肿瘤体积、三维能量多普勒指数及造影参数。
  • 病理缓解定义为完全缓解(治疗后无任何残留肿瘤)或部分缓解(病理检查见微观和/或宏观残留肿瘤)。

主要发现

  • 新辅助治疗完全病理缓解40例(45.5%),部分缓解48例(54.5%)。
  • 基线检查时两组肿瘤体积无差异;新辅助治疗2周后部分缓解组肿瘤体积显著大于完全缓解组(P=0.019)。
  • 三维血管指数中,部分缓解组VI在治疗前及治疗2周后均显著低于完全缓解组(P=0.037与P=0.024)。
  • 基线造影分析中,部分缓解组肿瘤峰值增强(PE)、肿瘤灌注洗入率(WiR)较低而肿瘤上升时间(RT)较长(P=0.006、P=0.003、P=0.038);治疗2周后造影参数无差异。

关键数值与推荐

  • 基线参数预测部分病理缓解的最佳截断值:VI 41.5%(敏感性63.6%,特异性66.7%);肿瘤PE 16123.5辅助单位(敏感性47.9%,特异性84.2%);肿瘤RT 7.8秒(敏感性68.8%,特异性57.9%);肿瘤WiR 4902(敏感性77.1%,特异性60.5%)。
  • 治疗2周后参数预测部分病理缓解的最佳截断值:肿瘤体积18.1 cm3(敏感性70.8%,特异性60.0%);VI 39.5%(敏感性62.5%,特异性73.5%)。

临床怎么用

  • 作者认为,治疗前与治疗2周后的超声参数截断值敏感性与特异性均不可接受,不能用于预测新辅助治疗的病理部分缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chemoradiation-based neoadjuvant treatment followed by radical surgery is an alternative therapeutic strategy for locally advanced cervical cancer (LACC), but ultrasound variables used to predict partial response to neoadjuvant treatment are not well defined. Our goal was to analyze prospectively the potential role of transvaginal ultrasound in early prediction of partial pathological response, assessed in terms of residual disease at histology, in a large, single-institution series of LACC patients triaged to neoadjuvant treatment followed by radical surgery. METHODS: Between October 2010 and June 2014, we screened 108 women with histologically documented LACC Stage IB2-IVA, of whom 88 were included in the final analysis. Tumor volume, three-dimensional (3D) power Doppler indices and contrast parameters were obtained before (baseline examination) and after 2 weeks of treatment. The pathological response was defined as complete (absence of any residual tumor after treatment) or partial (microscopic and/or macroscopic residual tumor at pathological examination). Complete-response and partial-response groups were compared and receiver-operating characteristics (ROC) curves were generated for ultrasound variables that were statistically significant on univariate analysis to evaluate their diagnostic ability to predict partial pathological response. RESULTS: There was a complete pathological response to neoadjuvant therapy in 40 (45.5%) patients and a partial response in 48 (54.5%). At baseline examination, tumor volume did not differ between the two groups. However, after 2 weeks of neoadjuvant treatment, the tumor volume was significantly greater in patients with partial response than it was in those with complete response (P = 0.019). Among the 3D vascular indices, the vascularization index (VI) was significantly lower in the partial-response compared with the complete-response group, both before and after 2 weeks of treatment (P = 0.037 and P = 0.024, respectively). At baseline examination in the contrast analysis, women with partial response had lower tumor peak enhancement (PE) as well as lower tumor wash-in rate (WiR) and longer tumor rise time (RT) compared with complete responders (P = 0.006, P = 0.003, P = 0.038, respectively). There was no difference in terms of contrast parameters after 2 weeks of treatment. ROC-curve analysis of baseline parameters showed that the best cut-offs for predicting partial pathological response were 41.5% for VI (sensitivity, 63.6%; specificity, 66.7%); 16123.5 auxiliary units for tumor PE (sensitivity, 47.9%; specificity, 84.2%); 7.8 s for tumor RT (sensitivity, 68.8%; specificity, 57.9%); and 4902 for tumor WiR (sensitivity, 77.1%; specificity, 60.5%). ROC curves of parameters after 2 weeks of treatment showed that the best cut-off for predicting partial pathological response was 18.1 cm3 for tumor volume (sensitivity, 70.8%; specificity 60.0%) and 39.5% for VI (sensitivity; 62.5%; specificity, 73.5%). CONCLUSIONS: Ultrasound and contrast parameters differ between LACC patients with complete response and those with partial response before and after 2 weeks of neoadjuvant treatment. However, neither ultrasound parameters before treatment nor those after 2 weeks of treatment had cut-off values with acceptable sensitivity and specificity for predicting partial pathological response to neoadjuvant therapy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Testa AC, Ferrandina G, Moro F, et al. PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery. Ultrasound Obstet Gynecol. 2018. PMID: 28620930. doi:10.1002/uog.17551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。